Ahmad Tarhini
Moffitt Cancer Center · ECOG-ACRIN Cancer Research Group · University of Pittsburgh
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
20
all conditions, ClinicalTrials.gov
NIH grants tied to them
1
NIH RePORTER
Trial papers
53
PubMed author-name match
Trials
Studies that name Ahmad Tarhini as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:40 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06295159 · Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma · principal investigator
- Ph2NCT06121180 · Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Metastatic Uveal Melanoma · principal investigator
- Ph2NCT05170334 · Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Metastatic Uveal Melanoma · principal investigator
- Ph1NCT04975152 · Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell CarcinomaH. Lee Moffitt Cancer Center and Research Institute · recruiting · Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma · principal investigator
- Ph2NCT04708418 · A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable MelanomaNational Cancer Institute (NCI) · active not recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Recurrent Cutaneous Melanoma · principal investigator
- Ph2NCT04562129 · IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma PatientsH. Lee Moffitt Cancer Center and Research Institute · active not recruiting · Melanoma Stage III, Melanoma Stage IV, Inoperable Disease · principal investigator
- Ph2NCT04526730 · Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma PatientsH. Lee Moffitt Cancer Center and Research Institute · completed · Melanoma · principal investigator
- Ph2NCT02796352 · A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker StudyAhmad Tarhini · terminated · Melanoma · principal investigator
- Ph1/Ph2NCT02736123 · Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab AloneUniversity of Pittsburgh · withdrawn · Melanoma · principal investigator
- Ph2NCT01708941 · Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7 · principal investigator
- Ph3NCT01274338 · Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryNational Cancer Institute (NCI) · active not recruiting · Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7 · principal investigator
- Ph2NCT01258855 · Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7 · principal investigator
- Ph1/Ph2NCT01233687 · AMG 102 and Erlotinib for Advanced Non-Small Cell Lung CancerAhmad Tarhini · completed · Carcinoma, Non-Small-Cell Lung · principal investigator
- Ph2NCT00932152 · Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung CancerUniversity of Pittsburgh · terminated · Non-small Cell Lung Cancer, Postmenopausal Women · principal investigator
- Ph1NCT00907179 · Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung CancerUniversity of Pittsburgh · terminated · Non-Small Cell Lung Cancer · principal investigator
- N/ANCT00889980 · Melanoma Molecular Profiling AnalysisUniversity of Pittsburgh · completed · Melanoma · principal investigator
- Early Ph1NCT00871533 · Pilot Study of IFN α2b for Melanoma PatientsUniversity of Pittsburgh · terminated · Melanoma · principal investigator
- Ph2NCT00610857 · Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV MelanomaAhmad Tarhini · completed · Melanoma · principal investigator
- Ph2NCT00450255 · VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma · principal investigator
- Ph2NCT00374140 · Phase II Trial of RAD001 (Everolimus) in Previously Treated Small Cell Lung CancerAhmad Tarhini · completed · Small Cell Lung Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Biomarkers of the Proinflammatory Response and Elements of Immune SuppressionP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2013 to 2017 · $292,902 awarded in 2017Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 2012 to 2013Named on NCT01708941, NCT01274338
- ECOG-ACRIN Biospecimen Bank to Support NCTNU24CA196172 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI STANLEY R. HAMILTON, Scott D Jewell · fiscal years 2015 to 2026Named on NCT01708941, NCT01274338
- Leadership, Planning and EvaluationP30CA033572 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI JOHN D. CARPTEN · fiscal years 2011 to 2026Named on NCT01258855, NCT00450255
- Experimental Therapeutics: Clinical Trials Network with Phase I EmphasisUM1CA186705 · NCI · UNIVERSITY OF CHICAGO · PI Michael L. Maitland, MARK J RATAIN, WALTER M. STADLER · fiscal years 2014 to 2015Named on NCT01258855
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:40 UTC. The ranking covers the 200 most relevant of 53 PubMed records, and a shared surname and initials can bring in a namesake. All 53 on PubMed
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.N Engl J Med · 20181,088 citationsRCR 35.8
- Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.J Clin Oncol · 2023403 citationsRCR 33.4
- 308 citationsRCR 7.6
- 296 citationsRCR 14.5
- PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines.Cancer Res · 2014187 citationsRCR 4.4
- Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.J Clin Oncol · 2020148 citationsRCR 5.2
- 127 citationsRCR 8.2
- Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.J Clin Oncol · 2012126 citationsRCR 2.7
- Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.Cancer Discov · 2022114 citationsRCR 6.3
- A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.Cancer · 2009106 citationsRCR 2.0